Position in SEPN
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$26,188,326
-$6,085,868 QoQ
Shares Held
1,089,818
-5.9% QoQ
Ownership
2.42%
of shares outstanding
% of Portfolio
1.65%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in SEPN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ADAR1 Capital Management, LLC holds $1,363,006,285 across 212 Biotechnology names. SEPN ranks #11 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,394,019 | $155,224,015 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
994,119 | $104,780,142 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,285,906 | $91,019,596 | |
| 4 | IMVT |
Immunovant, Inc.
|
2,679,010 | $66,546,608 | |
| 5 | TERN |
Terns Pharmaceuticals, Inc.
|
914,699 | $48,222,931 | |
| 6 | CYTK |
Cytokinetics Inc
|
632,556 | $41,691,765 | |
| 7 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
1,139,331 | $41,380,501 | |
| 8 | DNLI |
Denali Therapeutics Inc.
|
1,871,455 | $35,931,936 |
All Filings in SEPN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $26,188,326 | 1,089,818 | Shares | Sole | 2026-05-18 | |
| 2025-12-31 | $32,274,194 | 1,157,611 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $22,129,795 | 1,176,491 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $8,955,189 | 847,227 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $4,173,709 | 720,848 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||